Open Beta
TREN
MetriLume
TREN

US marketsARVN

SEC-sourced researchBeta

ARVN

ARVINAS, INC.

Company comparison ↗

Data passport

CIK
0001655759
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 28, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 78,500,000.0000 USD; December 2024: 263,400,000.0000 USD; December 2025: 262,600,000.0000 USD263.4M USD0 USD0December 2023December 2024December 2025
ARVN · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202378,500,000.0000Feb 24, 2026
December 2024263,400,000.0000Feb 24, 2026
December 2025262,600,000.0000Feb 24, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025262,600,000.0000-80,800,000.0000-273,800,000.0000717,900,000.0000284,000,000.0000Feb 24, 2026
December 2024263,400,000.0000-198,900,000.0000-259,300,000.00001,091,400,000.0000529,700,000.0000Feb 24, 2026
December 202378,500,000.0000-367,300,000.0000-347,800,000.0000——Feb 24, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

42/100
Profitability0
Growth50
Balance sheet60
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$262.6MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Previous period revenueRevenues$263.4MJan 1, 2024 – Dec 31, 2024Feb 24, 202610-K
Net incomeNetIncomeLoss-$80.8MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$273.8MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Total assetsAssets$717.9MDec 31, 2025Feb 24, 202610-K
Total liabilitiesLiabilities$284MDec 31, 2025Feb 24, 202610-K

New filings

Explore methodology ↗